Richard A. Messmann

4.7k total citations · 1 hit paper
49 papers, 3.2k citations indexed

About

Richard A. Messmann is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Richard A. Messmann has authored 49 papers receiving a total of 3.2k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Oncology, 15 papers in Pulmonary and Respiratory Medicine and 14 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Richard A. Messmann's work include Radiopharmaceutical Chemistry and Applications (11 papers), Prostate Cancer Treatment and Research (10 papers) and Acute Lymphoblastic Leukemia research (9 papers). Richard A. Messmann is often cited by papers focused on Radiopharmaceutical Chemistry and Applications (11 papers), Prostate Cancer Treatment and Research (10 papers) and Acute Lymphoblastic Leukemia research (9 papers). Richard A. Messmann collaborates with scholars based in United States, Germany and Canada. Richard A. Messmann's co-authors include Oliver Sartor, Michael J. Morris, Bernd J. Krause, Michelle DeSilvio, Karim Fizazi, Kim N., Johann S. de Bono, Kambiz Rahbar, Scott T. Tagawa and Tomasz M. Beer and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

Richard A. Messmann

48 papers receiving 3.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer

2021 1.5k citations Oliver Sartor, Johann S. de Bono et al. profile →

Peers

Richard A. Messmann

PRM

RNMI

ONCOL

Wouter B. Nagengast Netherlands

Valentina Boni Spain

Marjolijn N. Lub–de Hooge Netherlands

Scott N. Holden United States

Komal Jhaveri United States

Muralidhar Beeram United States

Paul Frankel United States

Stephen D. Rubin United States

Neville Davidson United Kingdom

Stéphane Culine France

Wouter B. Nagengast Netherlands

Richard A. Messmann

890 ×0.6

PRM

816 ×0.6

RNMI

1.2k ×1.0

ONCOL

787 ×0.8

388 ×1.1

Citations per year, relative to Richard A. Messmann Richard A. Messmann (= 1×) peers Wouter B. Nagengast

Countries citing papers authored by Richard A. Messmann

Since Specialization

Citations

This map shows the geographic impact of Richard A. Messmann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Richard A. Messmann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Richard A. Messmann more than expected).

Fields of papers citing papers by Richard A. Messmann

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Richard A. Messmann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Richard A. Messmann. The network helps show where Richard A. Messmann may publish in the future.

Co-authorship network of co-authors of Richard A. Messmann

This figure shows the co-authorship network connecting the top 25 collaborators of Richard A. Messmann. A scholar is included among the top collaborators of Richard A. Messmann based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Richard A. Messmann. Richard A. Messmann is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Morris, Michael J., Ana P. Kiess, Luke T. Nordquist, et al.. (2025). CONVERGE-01: Dosimetry, randomized dose optimization, dose escalation, and efficacy of ac-225 rosopatamab tetraxetan in participants with PSMA-positive castration-resistant prostate cancer.. Journal of Clinical Oncology. 43(5_suppl). 1 indexed citations

Fizazi, Karim, Ken Herrmann, Bernd J. Krause, et al.. (2021). 576MO Health-related quality of life (HRQoL), pain and safety outcomes in the phase III VISION study of 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer. Annals of Oncology. 32. S627–S628. 3 indexed citations

Harb, Wael A., Nehal J. Lakhani, Richard A. Messmann, Barbara Klencke, & Ayad Al‐Katib. (2021). A Phase 2 Study of PNT2258 for Treatment of Relapsed or Refractory B-Cell Malignancies. Clinical Lymphoma Myeloma & Leukemia. 21(12). 823–830. 3 indexed citations

Gampala, Silpa, et al.. (2020). The multifunctional APE1 DNA repair–redox signaling protein as a drug target in human disease. Drug Discovery Today. 26(1). 218–228. 76 indexed citations

Shah, Fenil, Derek P. Logsdon, Richard A. Messmann, et al.. (2017). Exploiting the Ref-1-APE1 node in cancer signaling and other diseases: from bench to clinic. Publisher. 1 indexed citations

Morris, Michael J., Nicholas J. Vogelzang, Oliver Sartor, et al.. (2017). Phase 1 study of the PSMA-targeted small-molecule drug conjugate EC1169 in patients with metastatic castrate-resistant prostate cancer (mCRPC). Annals of Oncology. 28. v273–v273. 5 indexed citations

Heertum, Ronald L. Van, Barbara Klencke, Richard A. Messmann, et al.. (2017). Lugano 2014 criteria for assessing FDG-PET/CT in lymphoma: an operational approach for clinical trials. Drug Design Development and Therapy. Volume 11. 1719–1728. 62 indexed citations

Shah, Fenil, Derek P. Logsdon, Richard A. Messmann, et al.. (2017). Exploiting the Ref-1-APE1 node in cancer signaling and other diseases: from bench to clinic. npj Precision Oncology. 1(1). 115 indexed citations

Naumann, R. Wendel, Robert L. Coleman, Robert A. Burger, et al.. (2013). PRECEDENT: A Randomized Phase II Trial Comparing Vintafolide (EC145) and Pegylated Liposomal Doxorubicin (PLD) in Combination Versus PLD Alone in Patients With Platinum-Resistant Ovarian Cancer. Journal of Clinical Oncology. 31(35). 4400–4406. 169 indexed citations

10.

Tolcher, Anthony W., Wendi V. Rodrigueza, Drew Rasco, et al.. (2013). A phase 1 study of the BCL2-targeted deoxyribonucleic acid inhibitor (DNAi) PNT2258 in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology. 73(2). 363–371. 70 indexed citations

11.

Harb, Wael A., Nehal J. Lakhani, Michael J. Woolliscroft, et al.. (2013). The BCL2 Targeted Deoxyribonucleic Acid Inhibitor (DNAi) PNT2258 Is Active In Patients With Relapsed Or Refractory Non-Hodgkin’s Lymphoma. Blood. 122(21). 88–88. 3 indexed citations

12.

Edelman, Martin J., Wael A. Harb, Ralph V. Boccia, et al.. (2012). Multicenter Trial of EC145 in Advanced, Folate-Receptor Positive Adenocarcinoma of the Lung. Journal of Thoracic Oncology. 7(10). 1618–1621. 33 indexed citations

13.

Leamon, Christopher P., Joseph A. Reddy, Patrick Klein, et al.. (2010). Reducing Undesirable Hepatic Clearance of a Tumor-Targeted Vinca Alkaloid via Novel Saccharopeptidic Modifications. Journal of Pharmacology and Experimental Therapeutics. 336(2). 336–343. 41 indexed citations

14.

Matteson, Eric L., Val J. Lowe, Franklyn G. Prendergast, et al.. (2009). Assessment of disease activity in rheumatoid arthritis using a novel folate targeted radiopharmaceutical Folatescan.. PubMed. 27(2). 253–9. 63 indexed citations

15.

Fisher, Ronald E., Barry A. Siegel, Steven L. Edell, et al.. (2008). Exploratory Study of ^99mTc-EC20 Imaging for Identifying Patients with Folate Receptor–Positive Solid Tumors. Journal of Nuclear Medicine. 49(6). 899–906. 127 indexed citations

16.

Sausville, E. A., P. LoRusso, Mary Quinn, et al.. (2007). A phase I study of EC145 administered weeks 1 and 3 of a 4-week cycle in patients with refractory solid tumors. Journal of Clinical Oncology. 25(18_suppl). 2577–2577. 14 indexed citations

17.

Sparreboom, Alex, Milin Acharya, Adrian M. Senderowicz, et al.. (2004). Effects of α1-Acid Glycoprotein on the Clinical Pharmacokinetics of 7-Hydroxystaurosporine. Clinical Cancer Research. 10(20). 6840–6846. 18 indexed citations

18.

Zhai, Suoping, Edward A. Sausville, Adrian M. Senderowicz, et al.. (2003). Clinical pharmacology and pharmacogenetics of flavopiridol 1-h i.v. infusion in patients with refractory neoplasms. Anti-Cancer Drugs. 14(2). 125–135. 20 indexed citations

19.

Messmann, Richard A., et al.. (2001). Quantitative determination of perifosine, a novel alkylphosphocholine anticancer agent, in human plasma by reversed-phase liquid chromatography–electrospray mass spectrometry. Journal of Chromatography B Biomedical Sciences and Applications. 759(2). 247–257. 19 indexed citations

20.

Schindler, John, E. A. Sausville, Richard A. Messmann, J W Uhr, & E S Vitetta. (2001). The toxicity of deglycosylated ricin A chain-containing immunotoxins in patients with non-Hodgkin's lymphoma is exacerbated by prior radiotherapy: a retrospective analysis of patients in five clinical trials.. PubMed. 7(2). 255–8. 39 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact